Charbel Nassar

Celiac drug trial results, updated prevalence data, a Brazilian labeling case, school guidance, and recalls — the latest in gluten-free research and policy.

A Cleveland Clinic AI model reaches 97% accuracy distinguishing celiac from normal biopsies, while a Norwegian study finds evidence of historical misdiagnosis. Plus long-term outcomes, COVID-19 risk and recalls.

Spain funds gluten-free diets, Sydney Airport’s labeling faces scrutiny, and four bills advance in Congress. Plus a drug acquisition and product recalls.

Tunisia funds gluten-free diets, Codex sets a global “may contain” gluten standard, and the UK updates celiac diagnosis guidance. Plus recalls.

The latest gluten-free news from around the world: a New Zealand hospital case, new celiac disease research from Norway, advocacy stories from Malta and Spain, and recent gluten-related recalls in the UK and France.

June’s gluten-free news: FDA’s labeling review, Virginia’s takeout law, beer testing gaps, a probiotic yeast study, and recalls in three countries.

Celiac disease raises the risk of death, heart disease, and organ failure — and two new studies published this week put the numbers on paper for the first time in the U.S. This edition also covers a landmark labeling bill, a stalled compensation law in Spain, and how major league baseball is stepping up for the celiac community.

Celiac disease raises the risk of eating disorders, a new drug shows effects beyond the gut, and a popular podcast reminded us why awareness still matters. This edition covers the latest research, recalls, and what the celiac community is talking about right now.

The latest edition of The Gluten-Free Brief covers major new celiac research, undiagnosed case estimates from Ireland, Québec, and the UK, gluten-related recalls in Canada, a U.S. court ruling on gluten-free meals, and formulation changes affecting Peanut M&M’s in New Zealand.